Abstract
Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.
Original language | English |
---|---|
Pages (from-to) | 521-534 |
Number of pages | 14 |
Journal | Clinics in Liver Disease |
Volume | 23 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1 Aug 2019 |